GlassScriptPhysician profile
Nicholas James Mcqueen
NPI 1336503028
$9,395.48
in general payments reported to CMS, 2019-2025
50 companies · $1,766 in 2025
The $1,766 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $1,338 · 2021: $1,515 · 2022: $1,218 · 2023: $1,567 · 2024: $1,752 · 2025: $1,766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,084.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,073.16 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $966.26 | 2021-2025 | |
| Novo Nordisk INC | $910.39 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $886.69 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $640.76 | 2019-2025 | Repatha, Evenity, Otezla |
| Astrazeneca Pharmaceuticals LP | $558.28 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $531.07 | 2019-2025 | |
| Antares Pharma, INC. | $415.43 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $357.86 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $301.32 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.07 | 2019-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Allergan, INC. | $246.71 | 2019-2020 | |
| Corium, LLC | $200.97 | 2023-2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $179.91 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $150.14 | 2023-2025 | Caplyta |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Mcqueen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.